Core Insights - BioMarin Pharmaceutical Inc. has acquired Amicus Therapeutics for $4.8 billion to enhance its market position in the rare genetic diseases sector against competitors like Alexion Pharmaceuticals and Vertex Pharmaceuticals [1][4] Acquisition Details - The acquisition involves purchasing all outstanding shares of Amicus at $14.50 per share, representing a 33% premium over its previous closing price [5] - The deal is financed through BioMarin's cash reserves and $3.7 billion in non-convertible debt, strategically avoiding equity dilution [2][6] - The acquisition is expected to close in the second quarter of 2026 and will add Amicus' therapies, Galafold and Pombiliti-Opfolda, which generated $449 million in sales in the first nine months of 2025, to BioMarin's portfolio [5][6] Market Reaction - Following the acquisition announcement, BioMarin's stock surged by 18%, while Amicus' stock increased by 30%, indicating strong investor confidence in the strategic benefits of the acquisition [2][7] - Joon Lee from Truist Financial set a price target of $100 for BioMarin, suggesting a potential upside of 68.7% from its trading price of $59.28 at the time of the announcement [4]